- Home
- FTHY vs CRMD Comparison
FTHY vs CRMD Comparison
Compare FTHY & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- CRMD
- Stock Information
- Founded
- FTHY 2020
- CRMD 2006
- Country
- FTHY United States
- CRMD United States
- Employees
- FTHY N/A
- CRMD N/A
- Industry
- FTHY Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- FTHY Finance
- CRMD Health Care
- Exchange
- FTHY Nasdaq
- CRMD Nasdaq
- Market Cap
- FTHY 500.1M
- CRMD 464.7M
- IPO Year
- FTHY N/A
- CRMD 2010
- Fundamental
- Price
- FTHY $14.06
- CRMD $12.03
- Analyst Decision
- FTHY
- CRMD Strong Buy
- Analyst Count
- FTHY 0
- CRMD 6
- Target Price
- FTHY N/A
- CRMD $15.00
- AVG Volume (30 Days)
- FTHY 176.7K
- CRMD 2.1M
- Earning Date
- FTHY 01-01-0001
- CRMD 05-06-2025
- Dividend Yield
- FTHY 10.93%
- CRMD N/A
- EPS Growth
- FTHY N/A
- CRMD N/A
- EPS
- FTHY N/A
- CRMD 0.28
- Revenue
- FTHY N/A
- CRMD $82,553,827.00
- Revenue This Year
- FTHY N/A
- CRMD $207.65
- Revenue Next Year
- FTHY N/A
- CRMD $50.13
- P/E Ratio
- FTHY N/A
- CRMD $43.34
- Revenue Growth
- FTHY N/A
- CRMD N/A
- 52 Week Low
- FTHY $12.66
- CRMD $3.61
- 52 Week High
- FTHY $14.74
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- FTHY 49.52
- CRMD 76.78
- Support Level
- FTHY $14.02
- CRMD $8.72
- Resistance Level
- FTHY $14.30
- CRMD $9.82
- Average True Range (ATR)
- FTHY 0.15
- CRMD 0.65
- MACD
- FTHY 0.03
- CRMD 0.42
- Stochastic Oscillator
- FTHY 57.75
- CRMD 94.49
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.